Hologic, Inc. (HOLX)
Automate Your Wheel Strategy on HOLX
With Tiblio's Option Bot, you can configure your own wheel strategy including HOLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOLX
- Rev/Share 13.4409
- Book/Share 21.5879
- PB 3.0952
- Debt/Equity 0.0028
- CurrentRatio 3.5547
- ROIC 0.0743
- MktCap 14890502900.0
- FreeCF/Share 4.3608
- PFCF 15.2224
- PE 26.9049
- Debt/Assets 0.0015
- DivYield 0
- ROE 0.1151
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HOLX | Citigroup | Neutral | Buy | -- | $80 | July 9, 2025 |
| Reiterated | HOLX | Needham | -- | Hold | -- | -- | May 27, 2025 |
| Downgrade | HOLX | Argus | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | HOLX | Leerink Partners | Outperform | Market Perform | $80 | $75 | Feb. 6, 2025 |
| Downgrade | HOLX | Needham | Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | HOLX | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Initiation | HOLX | Jefferies | -- | Hold | -- | $85 | Dec. 10, 2024 |
| Reiterated | HOLX | Needham | -- | Buy | -- | $90 | Dec. 10, 2024 |
| Downgrade | HOLX | Citigroup | Buy | Neutral | $95 | $85 | Oct. 1, 2024 |
News
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Read More
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Read More
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Read More
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
Read More
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
Read More
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX's Molecular Diagnostics growth stays resilient, as new assays and test adoption offset funding headwinds.
Read More
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Read More
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
Read More
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Read More
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
Read More
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hologic Climbs 13% in a Month: How Should You Play the Stock?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively.
Read More
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
Read More
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.
Read More
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone
Published: May 27, 2025 by: Proactive Investors
Sentiment: Neutral
TPG and Blackstone Inc (NYSE:BX), two private equity firms, have made a non-binding offer of more than $16 billion to take medical equipment-maker Hologic Inc (NASDAQ:HOLX) private, according to a media report from the Financial Times. Citing people with knowledge of the matter, the publication said Massachusetts-based Hologic has rejected the offer.
Read More
Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports
Published: May 27, 2025 by: Reuters
Sentiment: Negative
Medical equipment maker Hologic rejected a $16 billion non-binding offer from private equity firms TPG and Blackstone , the Financial Times reported on Tuesday, citing people familiar with the matter.
Read More
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more.
Read More
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test.
Read More
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Understanding Hologic (HOLX) Reliance on International Revenue
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.
Read More
Hologic: Soft Performance, But Cheap Enough
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Read More
About Hologic, Inc. (HOLX)
- IPO Date 1990-03-01
- Website https://www.hologic.com
- Industry Medical - Instruments & Supplies
- CEO Stephen P. MacMillan
- Employees 7063